BACKGROUND AND OBJECTIVES: Since previous studies have indicated there are improvements in overall survival, the aim of this phase II clinical study was to evaluate docetaxel every three weeks plus prednisone as first-line chemotherapy for treatment of hormone-refractory metastatic prostate cancer (HRMPC). METHODS: Thirty-five metastatic HRPC patients were treated with docetaxel 70 mg/m2 every 3 weeks plus oral prednisolone 5 mg twice daily at the clinical oncology departments of Tanta, Mansoura and Menofia University Hospitals during the period from June 2006 to December 2008. The primary endpoint was assessment of the overall tumor response rate. Secondary endpoints were assessment of PSA response rate, overall survival rate, and the time to disease progression. RESULTS: The median number of cycles administered was 6 cycles. Partial response was observed in 15 patients (42.9%) with evaluable measurable disease. Median survival from protocol entry was 15 months. Median timeto-disease progression was 10 months. Prostate-specific antigen (PSA) declined ≥ 50% in 9 patients (25.7%). The most common grade 3/4 toxicity associated with studied protocol was neutropenia (85.7%). CONCLUSIONS: When given with prednisone, treatment with docetaxel every three weeks does not improve survival, so the benefit of docetaxel-based therapy is not clear this high risk and poor prognostic group of pattients.
Background: The aim of this phase II clinical study was to evaluate three-weekly docetaxel plus prednisolone as firstline chemotherapy for treatment of hormone-refractory metastatic prostate cancer (HRMPC). Materials and Methods: Thirty five metastatic HRPC patients were treated with docetaxel 70 mg/m2 on Day 1, every 3 weeks plus oral prednisolone 5 mg twice daily at Clinical Oncology Departments, Tanta, Mansoura and Menofia University Hospitals during the period from June 2006 to December 2008. The primary endpoint was assessment of the overall tumor response rate. Secondary endpoints were assessment of PSA response rate, overall survival rate and the time to disease progression. Results: In 35 patients with metastatic HRPC, the median number of cycles administered was 6 cycles. Partial response was observed in 15 patients (42.9%) with evaluable measurable disease. Median survival from protocol entry was 12 months. Median time to disease progression was 9 months. Prostate-specific antigen (PSA) declined ≥50% in 9 patients (25.7%). The most common grade 34/ toxicity associated with studied protocol was neutropenia (85.7%). Conclusions: When given with prednisolone, treatment with docetaxel every three weeks lead to improved survival and response rates with accepted tolerability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.